For the first time there is hope for an effective drug treatment for chronic fatty liver disease (MASH). It is one of the most common causes of liver cirrhosis and liver carcinoma. In the USA, “Resmetirom”, the first drug with a positive effect proven by clinical studies, was recently approved. Other similar drugs are likely to follow.
MASH (formerly NASH – non-alcoholic steatohepatitis) is a chronic and progressive liver disease. It is estimated that around 115 million people are currently affected worldwide.
In principle, it is a progressive fatty liver with scarring of the organ (fibrosis).
In some of those affected, this ultimately progresses to liver failure (cirrhosis). Such illnesses are also common in people with chronic high alcohol consumption, but alcohol is not the cause in MASH.
Obesity and diabetes are often the prerequisites for the development of the disease. But MASH is also closely linked to kidney, cardiovascular or metabolic diseases. It is estimated that a third of people who are obese also have MASH.
In Europe, the German pharmaceutical company Boehringer Ingelheim, with its active ingredient survodutide, is apparently the furthest along in the development of such therapies for patients with chronic fatty liver disease.
My themes
For your saved topics were
new articles found.
info By clicking on the icon you can add the keyword to your topics.
info
By clicking on the icon you open your “my topics” page. They have of 15 keywords saved and would have to remove keywords.
info By clicking on the icon you can remove the keyword from your topics.
Add the topic to your topics.
Source: Nachrichten
